Abstract: Objective To summarize and analyze the dynamic change of HBsAg levels in patients with chronic Hepatitis B (CHB) after receiving nucleos(t)ide analogues (NAs) as antiviral treatment. Methods Patients who were performed quantitative Hepatitis B surface antigen(qHBsAg) from July 30, 2012 to December 30 ,2016 in Peking Union Medical College Hospital were retrospectively enrolled. QHBsAg, HBV DNA, quantitative HBeAg were collected and analyzed at baseline and at 192-week follow-up every 24 weeks. QHBsAg and quantitative HBeAg were assessed with CMIA .HBV DNA were assessed with PCR and COBAS Amplicor. Results 60 patients were included. Patients in HBeAg-positive group had higher HBV DNA than that in HBeAg-negative group （P＜0.05）at baseline and the two groups both were under detection limit after 48 weeks.Baseline qHBsAg in HBeAg positive-group and negative-group were (3.43±0.73) log10IU/mL, (3.08±0.47) log10IU/mL respectively .QHBsAg in HBeAg-positive group was higher than that in HBeAg negative-group on all follow-ups（P＜0.05） except 48weeks.However on 168 weeks and 192 weeks , difference between the two groups was statistically significant（P＜0.05）. In HBeAg-positive group,quantitative HBeAg dropped significantly during antiviral treatment. Conclusion HBV replication can be suppressed in the process of long-term NAs treatment in CHB patients.However qHBsAg decline is not so obvious, which indicates that HBsAg loss in the cure target is difficult,and long-term NAs therapy is still essential.

Key words: chronic hepatitis B, nucleos(t)ide analogues, quantitative hepatitis B surface antigen